ZA200800983B - GSK-3 inhibitors - Google Patents

GSK-3 inhibitors

Info

Publication number
ZA200800983B
ZA200800983B ZA200800983A ZA200800983A ZA200800983B ZA 200800983 B ZA200800983 B ZA 200800983B ZA 200800983 A ZA200800983 A ZA 200800983A ZA 200800983 A ZA200800983 A ZA 200800983A ZA 200800983 B ZA200800983 B ZA 200800983B
Authority
ZA
South Africa
Prior art keywords
gsk
inhibitors
Prior art date
Application number
ZA200800983A
Other languages
English (en)
Inventor
Martinez Gil Ana
Medina Padilla Miguel
Alonso Cascon Mercedes
Fuertes Huerta Ana
Navarro Rico Maria Luisa
Perez Puerto Maria Jose
Castro Morera Ana
Martin Aparicio Ester
Original Assignee
Neuropharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropharma Sa filed Critical Neuropharma Sa
Publication of ZA200800983B publication Critical patent/ZA200800983B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
ZA200800983A 2005-07-29 2006-07-28 GSK-3 inhibitors ZA200800983B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05380176A EP1749523A1 (en) 2005-07-29 2005-07-29 GSK-3 inhibitors

Publications (1)

Publication Number Publication Date
ZA200800983B true ZA200800983B (en) 2009-07-29

Family

ID=35445902

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800983A ZA200800983B (en) 2005-07-29 2006-07-28 GSK-3 inhibitors

Country Status (24)

Country Link
US (1) US8686042B2 (el)
EP (2) EP1749523A1 (el)
JP (1) JP5484726B2 (el)
KR (1) KR101471999B1 (el)
CN (1) CN101257900B (el)
AU (1) AU2006278829B2 (el)
BR (1) BRPI0615968B1 (el)
CA (1) CA2616451C (el)
CY (1) CY1119971T1 (el)
DK (1) DK1919465T3 (el)
ES (1) ES2661326T3 (el)
HK (1) HK1124761A1 (el)
HR (1) HRP20180109T1 (el)
HU (1) HUE036844T2 (el)
IL (1) IL189048A (el)
LT (1) LT1919465T (el)
NO (1) NO341454B1 (el)
NZ (1) NZ566380A (el)
PL (1) PL1919465T3 (el)
PT (1) PT1919465T (el)
RU (1) RU2449998C2 (el)
SI (1) SI1919465T1 (el)
WO (1) WO2007017145A2 (el)
ZA (1) ZA200800983B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2091943B1 (en) 2006-10-21 2013-11-20 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
JP2011511042A (ja) * 2008-02-06 2011-04-07 ノスシラ、ソシエダッド、アノニマ 認知、神経変性または神経疾患または障害の処置のための海産および合成起源のフェニル−プレニル誘導体
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009130317A1 (en) * 2008-04-24 2009-10-29 Abbott Gmbh & Co. Kg 1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
WO2010148197A1 (en) 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2854539A4 (en) * 2012-05-14 2016-03-09 Univ Kansas PHOSPHONATE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HUE049377T2 (hu) 2013-03-14 2020-09-28 Brigham & Womens Hospital Inc Készítmények és eljárások epiteliális õssejtek expanziójára és tenyésztésére
JP6615755B2 (ja) 2013-11-13 2019-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルスの複製の阻害剤
SG10201804021TA (en) 2013-11-13 2018-07-30 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
CN106727556B (zh) * 2016-11-30 2017-10-20 鑫喆喆 一种治疗脑损伤的药物组合物
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895625A (en) * 1957-12-27 1962-05-02 Hoechst Ag New benzene-sulphonyl benzyl-ureas and process of preparing them
ES474449A1 (es) * 1978-10-23 1979-05-01 Invest Tecnica Aplicada Procedimiento de obtencion de ureas y tioureas con actividad farmacologica.
DE3371508D1 (en) * 1983-01-24 1987-06-19 Duphar Int Res Benzoylurea compounds, and pesticidal and pharmaceutical compositions comprising same
JPH10182588A (ja) * 1996-10-30 1998-07-07 Ss Pharmaceut Co Ltd 置換ベンジル尿素誘導体及びこれを含有する医薬
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
DE69806042T2 (de) * 1997-11-07 2003-01-23 Schering Corp., Kenilworth Phenylalkyl imidazole derivate als h3 rezeptor liganden
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
JP2003527360A (ja) * 2000-03-14 2003-09-16 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
CA2424246A1 (en) * 2000-10-02 2002-04-11 Shianlen Cahoon Methods and compositions for the treatment of inflammatory diseases
SE0102440D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compound
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
JP4613130B2 (ja) * 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
US8686042B2 (en) 2014-04-01
JP2009502846A (ja) 2009-01-29
NO341454B1 (no) 2017-11-13
US20090124686A1 (en) 2009-05-14
CA2616451C (en) 2015-01-20
AU2006278829A1 (en) 2007-02-15
CN101257900B (zh) 2012-09-12
WO2007017145A2 (en) 2007-02-15
IL189048A (en) 2017-04-30
EP1749523A1 (en) 2007-02-07
JP5484726B2 (ja) 2014-05-07
WO2007017145A3 (en) 2007-04-26
AU2006278829B2 (en) 2012-03-29
BRPI0615968B1 (pt) 2023-10-03
HK1124761A1 (en) 2009-07-24
HRP20180109T1 (hr) 2018-04-20
NZ566380A (en) 2011-01-28
PL1919465T3 (pl) 2018-06-29
CN101257900A (zh) 2008-09-03
RU2449998C2 (ru) 2012-05-10
KR101471999B1 (ko) 2014-12-10
CA2616451A1 (en) 2007-02-15
RU2008107733A (ru) 2009-09-10
IL189048A0 (en) 2008-08-07
SI1919465T1 (en) 2018-04-30
DK1919465T3 (en) 2018-02-05
BRPI0615968A2 (pt) 2011-05-31
EP1919465B1 (en) 2017-12-27
KR20080031440A (ko) 2008-04-08
LT1919465T (lt) 2018-04-10
EP1919465A2 (en) 2008-05-14
PT1919465T (pt) 2018-03-07
CY1119971T1 (el) 2018-12-12
HUE036844T2 (hu) 2018-08-28
ES2661326T3 (es) 2018-03-28
NO20081052L (no) 2008-02-28

Similar Documents

Publication Publication Date Title
IL189048A0 (en) Gsk-3 inhibitors
IL178125A0 (en) Gsk-3 inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
HK1122041A1 (en) Heterobifunctional pan-selectin inhibitors
PL2383271T3 (pl) Aminochinolony jako inhibitory GSK-3
IL190078A0 (en) Kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
EP1971595A4 (en) CETP INHIBITORS
EP1973889A4 (en) CETP INHIBITORS
ZA200802867B (en) Fap inhibitors
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
EP1906945A4 (en) HCV INHIBITORS
EP1926485A4 (en) HIF-INHIBITORS
PL1943243T3 (pl) Inhibitory kinazy
ZA200805386B (en) MIF inhibitors
IL188850A0 (en) Cathepsin k inhibitors
EP1951053A4 (en) CETP INHIBITORS
GB0515327D0 (en) Comt inhibitors
GB0421355D0 (en) Inhibitors
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
ZA200711069B (en) HCV inhibitors